Flow	B:C0022885
-	I:C0022885
Induced	I:C0022885
Dispersion	I:C0022885
Analysis	I:C0022885
for	O
Probing	B:C0022885
Anti-dsDNA	B:C2746079
Antibody	I:C2746079
Binding	B:C1167622
Heterogeneity	O
in	O
Systemic	B:C0024141
Lupus	I:C0024141
Erythematosus	I:C0024141
Patients	O
:	O
Toward	O
a	O
New	O
Approach	O
for	O
Diagnosis	B:C1704656
and	O
Patient	O
Stratification	B:C1514983
.	O

Detection	B:C1511790
of	O
immune	B:C0301872
responses	I:C0301872
is	O
important	O
in	O
the	O
diagnosis	B:C1704656
of	O
many	O
diseases	B:C0012634
.	O

For	O
example	O
,	O
the	O
detection	B:C1511790
of	O
circulating	O
autoantibodies	B:C0004358
against	O
double	B:C0311474
-	I:C0311474
stranded	I:C0311474
DNA	I:C0311474
(	O
double	B:C0311474
-	I:C0311474
stranded	I:C0311474
DNA	I:C0311474
)	O
is	O
used	O
in	O
the	O
diagnosis	B:C1704656
of	O
Systemic	B:C0024141
Lupus	I:C0024141
Erythematosus	I:C0024141
(	O
Systemic	B:C0024141
Lupus	I:C0024141
Erythematosus	I:C0024141
)	O
.	O

It	O
is	O
,	O
however	O
,	O
difficult	O
to	O
reach	O
satisfactory	O
sensitivity	O
,	O
specificity	O
,	O
and	O
accuracy	O
with	O
established	O
assays	B:C0005507
.	O

Also	O
,	O
existing	O
methodologies	B:C0086912
for	O
quantification	O
of	O
autoantibodies	B:C0004358
are	O
challenging	O
to	O
transfer	O
to	O
a	O
point	O
-	O
of	O
-	O
care	O
setting	O
.	O

Here	O
we	O
present	O
the	O
use	O
of	O
flow	B:C0022885
-	I:C0022885
induced	I:C0022885
dispersion	I:C0022885
analysis	I:C0022885
(	O
flow	B:C0242481
-	I:C0242481
induced	I:C0242481
dispersion	I:C0242481
analysis	I:C0242481
)	O
for	O
rapid	O
(	O
minutes	O
)	O
measurement	B:C1272321
of	I:C1272321
autoantibodies	I:C1272321
against	O
double	B:C0311474
-	I:C0311474
stranded	I:C0311474
DNA	I:C0311474
.	O

The	O
assay	B:C0005507
is	O
based	O
on	O
Taylor	B:C0022885
dispersion	I:C0022885
analysis	I:C0022885
(	O
Taylor	B:C0242481
dispersion	I:C0242481
analysis	I:C0242481
)	O
and	O
is	O
fully	O
automated	O
with	O
the	O
use	O
of	O
standard	O
capillary	B:C0201699
electrophoresis	I:C0201699
(	O
capillary	B:C0201699
electrophoresis	I:C0201699
)	O
based	O
equipment	O
employing	O
fluorescence	O
detection	B:C1511790
.	O

It	O
is	O
robust	O
toward	O
matrix	O
effects	O
as	O
demonstrated	O
by	O
the	O
direct	O
analysis	B:C1303103
of	I:C1303103
samples	I:C1303103
composed	O
of	O
up	O
to	O
85	O
%	O
plasma	B:C0032105
derived	O
from	O
human	B:C0086418
blood	B:C0178913
samples	I:C0178913
,	O
and	O
it	O
allows	O
for	O
flexible	B:C4019011
exchange	I:C4019011
of	O
the	O
DNA	B:C0162326
sequences	I:C0162326
used	O
to	O
probe	B:C0012893
for	O
the	O
autoantibodies	B:C0004358
.	O

Plasma	B:C0444263
samples	I:C0444263
from	O
Systemic	B:C0024141
Lupus	I:C0024141
Erythematosus	I:C0024141
positive	B:C1446409
patients	O
were	O
analyzed	B:C0936012
using	O
the	O
new	O
flow	B:C0242481
-	I:C0242481
induced	I:C0242481
dispersion	I:C0242481
analysis	I:C0242481
methodology	B:C0086912
as	O
well	O
as	O
by	O
standard	O
indirect	O
immunofluorescence	B:C0079603
and	O
solid	B:C0005507
-	I:C0005507
phase	I:C0005507
immunoassays	I:C0005507
.	O

Interestingly	O
,	O
the	O
patient	O
antibodies	B:C0003241
bound	B:C1167622
DNA	B:C0162326
sequences	I:C0162326
with	O
different	O
affinities	O
,	O
suggesting	O
pronounced	O
heterogeneity	O
among	O
autoantibodies	B:C0004358
produced	O
in	O
Systemic	B:C0024141
Lupus	I:C0024141
Erythematosus	I:C0024141
.	O

The	O
flow	B:C0242481
-	I:C0242481
induced	I:C0242481
dispersion	I:C0242481
analysis	I:C0242481
based	O
methodology	B:C0086912
is	O
a	O
new	O
approach	O
for	O
autoantibody	B:C0004358
detection	B:C1511790
and	O
holds	O
promise	O
for	O
being	O
used	O
for	O
patient	O
stratification	B:C1514983
and	O
monitoring	B:C1283169
of	I:C1283169
disease	I:C1283169
activity	I:C1283169
.	O

